Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors

2019-02-04

The Pharmacogenomics Journal , Volume 19 - Issue 5 p. 473- 479

Additional Metadata
Persistent URL	doi.org/10.1038/s41397-019-0079-z, hdl.handle.net/1765/121192
Journal	The Pharmacogenomics Journal
Rights	no subscription
Organisation	Rheumatology
Citation APA APA Style APA-ALL Style AAA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Verboom, MC, Kloth, J., Swen, J., Sleijfer, S., Reyners, AK, Steeghs, N., Mathijssen, R., Gelderblom, H.& Guchelaar, H. J. (2019). Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors. The Pharmacogenomics Journal, 19(5), 473–479.https://doi.org/10.1038/s41397-019-0079-z

Publication